Compare EPAC & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | AMLX |
|---|---|---|
| Founded | 1910 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1994 | 2021 |
| Metric | EPAC | AMLX |
|---|---|---|
| Price | $37.06 | $22.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $48.00 | $21.56 |
| AVG Volume (30 Days) | 400.7K | ★ 2.0M |
| Earning Date | 03-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | 8.97 | ★ 65.46 |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $616,899,000.00 | $380,786,000.00 |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $5.56 | N/A |
| P/E Ratio | $30.10 | ★ N/A |
| Revenue Growth | 4.65 | ★ 1612.94 |
| 52 Week Low | $32.35 | $7.63 |
| 52 Week High | $45.00 | $24.60 |
| Indicator | EPAC | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 61.21 |
| Support Level | $36.79 | $12.46 |
| Resistance Level | $37.57 | N/A |
| Average True Range (ATR) | 0.82 | 1.48 |
| MACD | 0.10 | 0.20 |
| Stochastic Oscillator | 75.29 | 69.48 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.